These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3111893)

  • 1. Utilization of luteinizing hormone-releasing hormone agonist in pulmonary leiomyomatosis.
    Maheux R; Samson Y; Farid NR; Parent JG; Jean C
    Fertil Steril; 1987 Aug; 48(2):315-7. PubMed ID: 3111893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of LHRH analogue to obtain reversible castration in a patient with benign metastasizing leiomyoma.
    Hague WM; Abdulwahid NA; Jacobs HS; Craft I
    Br J Obstet Gynaecol; 1986 May; 93(5):455-60. PubMed ID: 3085706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of uterine leiomyomata with a luteinizing hormone-releasing hormone agonist: the possibility of nonsurgical management in selected perimenopausal women.
    Nakamura Y; Yoshimura Y; Yamada H; Ubukata Y; Ando M; Suzuki M
    Fertil Steril; 1991 May; 55(5):900-5. PubMed ID: 1902420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a pilot study.
    Maheux R; Guilloteau C; Lemay A; Bastide A; Fazekas AT
    Am J Obstet Gynecol; 1985 Aug; 152(8):1034-8. PubMed ID: 3927734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-related inhibition of acute luteinizing hormone response during luteinizing hormone-releasing hormone agonist treatment for uterine leiomyoma.
    Maheux R; Lemay A; Turcot-Lemay L
    Am J Obstet Gynecol; 1988 Feb; 158(2):361-4. PubMed ID: 3124621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential reduction in the volume of leiomyoma and uterus during buserelin treatment.
    Puzigaća Z; Prelević GM; Sretenović Z
    Gynecol Endocrinol; 1994 Mar; 8(1):39-43. PubMed ID: 8059616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase.
    Healy DL; Lawson SR; Abbott M; Baird DT; Fraser HM
    J Clin Endocrinol Metab; 1986 Sep; 63(3):619-25. PubMed ID: 3090092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uterine leiomyosarcoma diagnosed during treatment with agonist of luteinizing hormone-releasing hormone for presumed uterine fibroid.
    Loong EP; Wong FW
    Fertil Steril; 1990 Sep; 54(3):530-1. PubMed ID: 2118862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of leiomyomata uteri with D-Trp6-luteinizing hormone-releasing hormone.
    Perl V; Marquez J; Schally AV; Comaru-Schally AM; Leal G; Zacharias S; Gomez-Lira C
    Fertil Steril; 1987 Sep; 48(3):383-9. PubMed ID: 2957235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uterine leiomyosarcomas coexistent with cellular and atypical leiomyomata in a young woman during the treatment with luteinizing hormone-releasing hormone agonist.
    Lee WY; Tzeng CC; Chou CY
    Gynecol Oncol; 1994 Jan; 52(1):74-9. PubMed ID: 8307505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin.
    Matta WH; Shaw RW; Nye M
    Br J Obstet Gynaecol; 1989 Feb; 96(2):200-6. PubMed ID: 2495020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of leiomyomas with luteinizing hormone-releasing hormone agonist].
    Nakamura Y; Yoshimura Y; Yamada H; Maruyama K; Nanno T; Ubukata Y; Ando M; Takahashi K; Suzuki M
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Dec; 42(12):1620-6. PubMed ID: 2126024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of uterine leiomyomas in perimenopausal women with gonadotropin-releasing hormone agonists.
    Nakamura Y; Yoshimura Y
    Clin Obstet Gynecol; 1993 Sep; 36(3):660-7. PubMed ID: 8403612
    [No Abstract]   [Full Text] [Related]  

  • 14. Subcutaneous injection or infusion of gonadotropin releasing-hormone agonist buserelin in the treatment of enlarged uteri harboring leiomyomata.
    Franssen AM; Willemsen WN; Corbey RS; Doesburg WH; van 't Veen AJ; Rolland R
    Eur J Obstet Gynecol Reprod Biol; 1991 Jul; 40(3):221-8. PubMed ID: 1908799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uterine leiomyoma and LHRH agonist treatment. A preliminary report.
    Rolland R; Franssen AM; Willemsen WN; Corbey RS
    Prog Clin Biol Res; 1986; 225():313-20. PubMed ID: 3097670
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis.
    Friedman AJ; Lobel SM; Rein MS; Barbieri RL
    Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1114-9. PubMed ID: 2145765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uterine leiomyoma: treatment with LHRH agonist.
    Maheux R; Lemay A
    Prog Clin Biol Res; 1986; 225():297-311. PubMed ID: 3097669
    [No Abstract]   [Full Text] [Related]  

  • 18. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis.
    Lemay A; Maheux R; Faure N; Jean C; Fazekas AT
    Fertil Steril; 1984 Jun; 41(6):863-71. PubMed ID: 6427019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regression of leiomyomata uteri following hypoestrogenism induced by repetitive luteinizing hormone-releasing hormone agonist treatment: preliminary report.
    Maheux R; Guilloteau C; Lemay A; Bastide A; Fazekas AT
    Fertil Steril; 1984 Oct; 42(4):644-6. PubMed ID: 6436065
    [No Abstract]   [Full Text] [Related]  

  • 20. [Medical treatment of uterine leiomyomatosis with an agonist of pituitary gonadotropins (GnRH). Presentation of a case].
    Bustos HH; López Garcia R; Sánchez V; Contreras J; Ayala Ruiz A
    Ginecol Obstet Mex; 1990 Sep; 58():260-4. PubMed ID: 2125961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.